News Center

ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights

ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer

ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023

ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development

ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

ACELYRIN, INC. Reports First Quarter 2023 Financial Results And Recent Highlights

ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering

ACELYRIN, INC. Announces Launch of IPO Roadshow

ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy

Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors

ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa

ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio